Literature DB >> 1466657

Familial defective apolipoprotein B-100: a single mutation that causes hypercholesterolemia and premature coronary artery disease.

A Tybjaerg-Hansen1, S E Humphries.   

Abstract

Familial defective apolipoprotein B-100 is a recently identified, dominantly inherited genetic disorder caused by a G to A mutation in exon 26 of the apolipoprotein B gene. This creates a substitution of glutamine for arginine in the codon for amino acid 3500 and results in reduced affinity of low density lipoprotein (LDL) to the LDL receptor. We have integrated already published data with hitherto unpublished data from 8 countries and a total of 135 affected individuals from 56 families, in an attempt to focus on the range of expression of this mutation on lipid and lipoprotein levels and on coronary artery disease. The frequency of this mutation may be as high as 1 in 500 to 1 in 700 in Europe and in North America. The vast majority of affected heterozygotes have total and LDL cholesterol levels well above the 95th centile for age and gender; in contrast, high density lipoprotein cholesterol, very low density lipoprotein cholesterol and plasma triglycerides are not affected by the mutation. The risk of premature coronary artery disease in the carriers of the mutation is increased to levels as high as those seen in patients with clinical familial hypercholesterolemia; at age 50, about 40% of males and 20% of females heterozygous for the mutation have developed coronary artery disease. Familial defective apolipoprotein B-100 is thus a significant cause of hypercholesterolemia and premature coronary artery disease in Western societies.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1466657     DOI: 10.1016/0021-9150(92)90056-m

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  20 in total

Review 1.  Candidate genes and confirmed genetic polymorphisms associated with cardiovascular diseases: a tabular assessment.

Authors:  Z Tang; R P Tracy
Journal:  J Thromb Thrombolysis       Date:  2001-02       Impact factor: 2.300

2.  Randomised by (your) god: robust inference from an observational study design.

Authors:  George Davey Smith
Journal:  J Epidemiol Community Health       Date:  2006-05       Impact factor: 3.710

Review 3.  Mendelian randomization: can genetic epidemiology help redress the failures of observational epidemiology?

Authors:  Shah Ebrahim; George Davey Smith
Journal:  Hum Genet       Date:  2007-11-23       Impact factor: 4.132

Review 4.  Familial defective apolipoprotein B-100: a cause of hypercholesterolemia and early coronary heart disease.

Authors:  B A Nassar
Journal:  CMAJ       Date:  1993-02-15       Impact factor: 8.262

5.  European workshop on LDL receptor defects. European Working Group on Familial Hypercholesterolaemia.

Authors:  H Schuster; S Humphries
Journal:  Clin Investig       Date:  1994-11

6.  The plasma concentration of HDL-associated apoM is influenced by LDL receptor-mediated clearance of apoB-containing particles.

Authors:  Christina Christoffersen; Marianne Benn; Pernille M Christensen; Philip L S M Gordts; Anton J M Roebroek; Ruth Frikke-Schmidt; Anne Tybjaerg-Hansen; Björn Dahlbäck; Lars B Nielsen
Journal:  J Lipid Res       Date:  2012-07-23       Impact factor: 5.922

7.  Detection of apoB-100 R3500Q mutation by competitive allele-specific polymerase chain reaction.

Authors:  A D Horvath; S A Kirov; E E Karaulanov; V S Ganev
Journal:  J Clin Lab Anal       Date:  2001       Impact factor: 2.352

8.  Sib-pair analysis detects elevated Lp(a) levels and large variation of Lp(a) concentration in subjects with familial defective ApoB.

Authors:  Y Y van der Hoek; A Lingenhel; H G Kraft; J C Defesche; J J Kastelein; G Utermann
Journal:  J Clin Invest       Date:  1997-05-01       Impact factor: 14.808

Review 9.  Susceptibility mutations for ischemic heart disease.

Authors:  B G Nordestgaard; A Tybjaerg-Hansen
Journal:  Curr Atheroscler Rep       Date:  1999-09       Impact factor: 5.113

10.  Treatment of patients with familial defective apolipoprotein B-100 with pravastatin and gemfibrozil: a two-period cross-over study.

Authors:  P S Hansen; H Meinertz; L U Gerdes; I C Klausen; O Faergeman
Journal:  Clin Investig       Date:  1994-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.